| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
CC618 targets PPARβ/δ (peroxisome proliferator-activated receptor beta/delta). It selectively antagonizes agonist-induced PPARβ/δ activity. The compound covalently binds to PPARβ/δ receptors, displaying antagonistic effects. This inhibits PPARβ/δ-mediated transcriptional activity and downstream signaling pathways.
|
|---|---|
| ln Vitro |
CC618 is a potent and selective PPARβ/δ antagonist. It selectively antagonizes agonist-induced PPARβ/δ activity with an IC50 of 10.0 μM. The compound covalently binds to PPARβ/δ receptors.
|
| ln Vivo |
Specific in vivo activity data for CC618 is not extensively detailed in the available literature. As a research compound, its in vivo effects are primarily studied in the context of PPARβ/δ inhibition and its impact on metabolism, inflammation, and other physiological processes. Further studies are needed to fully characterize its in vivo efficacy and pharmacokinetic properties.
|
| Enzyme Assay |
CC618's activity as a PPARβ/δ antagonist is assessed using in vitro receptor binding and functional assays. Binding assays measure the compound's affinity for PPARβ/δ. Functional assays, such as reporter gene assays, measure its ability to antagonize agonist-induced PPARβ/δ transcriptional activity. The IC50 of 10.0 μM is determined from dose-response curves.
|
| Cell Assay |
Cellular assays for CC618 involve treating cells with the compound and measuring PPARβ/δ-mediated gene expression. Reporter gene assays, where cells are transfected with a PPARβ/δ-responsive luciferase reporter, are commonly used. The compound's effects on PPARβ/δ target gene expression are assessed by qRT-PCR.
|
| Animal Protocol |
In vivo animal model protocols for CC618 would involve its administration to animal models to study the role of PPARβ/δ in various diseases. Studies may include models of metabolic syndrome, inflammation, and cancer. The compound's effects on PPARβ/δ activity and disease phenotypes would be assessed.
|
| ADME/Pharmacokinetics |
CC618 has a molecular weight of 523.47 and a molecular formula of C20H15F6N3O3S2. Specific pharmacokinetic data is not extensively detailed in the available literature. As a small molecule inhibitor, its pharmacokinetic properties would need to be evaluated in preclinical studies.
|
| Toxicity/Toxicokinetics |
The toxicological profile of CC618 has not been extensively characterized. As a research compound, it is intended for research use only and not for human consumption. Standard safety assessments would be required for clinical development.
|
| References | |
| Additional Infomation |
Antagonists of PPARβ and PPARδ; structures are described in the first article.
CC618 (CAS# 1680204-90-3) is a research compound used to study PPARβ/δ function. It is a selective PPARβ/δ antagonist that covalently binds to the receptor. It is not approved for clinical use and is supplied as a research chemical. |
| Molecular Formula |
C20H15F6N3O3S2
|
|---|---|
| Molecular Weight |
523.4718
|
| Exact Mass |
523.045
|
| CAS # |
1680204-90-3
|
| PubChem CID |
118734332
|
| Appearance |
White to off-white solid powder
|
| LogP |
4.6
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
12
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
34
|
| Complexity |
810
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC1=C(SC(=N1)C2=CC=C(C=C2)C(F)(F)F)C(=O)NCCS(=O)(=O)C3=NC=C(C=C3)C(F)(F)F
|
| InChi Key |
AZZXDJUUKNGRAK-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C20H15F6N3O3S2/c1-11-16(33-18(29-11)12-2-4-13(5-3-12)19(21,22)23)17(30)27-8-9-34(31,32)15-7-6-14(10-28-15)20(24,25)26/h2-7,10H,8-9H2,1H3,(H,27,30)
|
| Chemical Name |
4-methyl-2-[4-(trifluoromethyl)phenyl]-N-[2-[5-(trifluoromethyl)pyridin-2-yl]sulfonylethyl]-1,3-thiazole-5-carboxamide
|
| Synonyms |
CC 618; CC-618; CC618
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9103 mL | 9.5516 mL | 19.1033 mL | |
| 5 mM | 0.3821 mL | 1.9103 mL | 3.8207 mL | |
| 10 mM | 0.1910 mL | 0.9552 mL | 1.9103 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
